269 related articles for article (PubMed ID: 32308053)
1. An overview on natural farnesyltransferase inhibitors for efficient cancer therapy.
Dai X; Sun Y; Zhang T; Ming Y; Hongwei G
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1027-1044. PubMed ID: 32308053
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of farnesyltransferase: a rational approach to treat cancer?
Puntambekar DS; Giridhar R; Yadav MR
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
[TBL] [Abstract][Full Text] [Related]
4. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.
Klochkov SG; Neganova ME; Yarla NS; Parvathaneni M; Sharma B; Tarasov VV; Barreto G; Bachurin SO; Ashraf GM; Aliev G
Semin Cancer Biol; 2019 Jun; 56():128-134. PubMed ID: 29100957
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
Pan J; Yeung SC
Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
8. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
[TBL] [Abstract][Full Text] [Related]
9. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
Basso AD; Kirschmeier P; Bishop WR
J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
[TBL] [Abstract][Full Text] [Related]
10. Phenothiazine-based CaaX competitive inhibitors of human farnesyltransferase bearing a cysteine, methionine, serine or valine moiety as a new family of antitumoral compounds.
Dumitriu GM; Bîcu E; Belei D; Rigo B; Dubois J; Farce A; Ghinet A
Bioorg Med Chem Lett; 2015 Oct; 25(20):4447-52. PubMed ID: 26372651
[TBL] [Abstract][Full Text] [Related]
11. New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.
Moise IM; Ghinet A; Belei D; Dubois J; Farce A; Bîcu E
Bioorg Med Chem Lett; 2016 Aug; 26(15):3730-4. PubMed ID: 27282741
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors.
Sebti SM; Adjei AA
Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
[TBL] [Abstract][Full Text] [Related]
13. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
14. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity.
Dinsmore CJ; Bell IM
Curr Top Med Chem; 2003; 3(10):1075-93. PubMed ID: 12769709
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitor as anticancer agent.
Agrawal AG; Somani RR
Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490
[TBL] [Abstract][Full Text] [Related]
18. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
20. Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity.
Moise IM; Bîcu E; Farce A; Dubois J; Ghinet A
Bioorg Chem; 2020 Oct; 103():104184. PubMed ID: 32891861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
